Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Visuomotor Prosthetic for Paralysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01958086
Recruitment Status : Recruiting
First Posted : October 8, 2013
Last Update Posted : April 13, 2022
Sponsor:
Collaborators:
University of California, Los Angeles
Casa Colina Hospital and Centers for Healthcare
Information provided by (Responsible Party):
Richard A. Andersen, PhD, California Institute of Technology

Brief Summary:
The investigators objective is to run human clinical trials in which brain activity recorded through a "brain-chip" implanted in the human brain can be used to provide novel communication capabilities to severely paralyzed individuals by allowing direct brain-control of a computer interface. A prospective, longitudinal, single-arm early feasibility study will be used to examine the safety and effectiveness of using a neural communication system to control a simple computer interface and a tablet computer. Initial brain control training will occur in simplified computer environments, however, the ultimate objective of the clinical trial is to allow the human patient autonomous control over the Google Android tablet operating system. Tablet computers offer a balance of ease of use and functionality that should facilitate fusion with the BMI. The tablet interface could potentially allow the patient population to make a phone call, manage personal finances, watch movies, paint pictures, play videogames, program applications, and interact with a variety of "smart" devices such as televisions, kitchen appliances, and perhaps in time, devices such as robotic limbs and smart cars. Brain control of tablet computers has the potential to greatly improve the quality of life of severely paralyzed individuals. Five subjects will be enrolled, each implanted with the NCS for a period of at least 53 weeks and up to 313 weeks. The study is expected to take at least one year and up to six years in total.

Condition or disease Intervention/treatment Phase
Quadriplegia Device: Neural Communication System Not Applicable

Detailed Description:

The objective of the proposed research is to obtain scientific knowledge of visuomotor transformations in posterior parietal cortex (PPC) and primary motor cortex (M1) from tetraplegic subjects in a clinical trial to advance the development of neural prosthetics. We have shown in clinical trials conducted over the past 6 years that PPC can control neural prosthetics for assisting tetraplegic subjects. Other groups have concentrated on M1 and likewise find control for neural prosthetics. In our studies of PPC we have found that besides trajectory signals to move robotic limbs or control computer cursors, there are a plethora of visuomotor signals that represent intended movements of most of the body, movement goals, cognitive strategies, and even memory signals. Our central hypothesis is that PPC and M1 will encode visuomotor parameters in both similar and different ways, and that algorithms can be developed to leverage those signals from the two areas that are complimentary to improve prosthetic range and performance. Implants will be made in both M1 and PPC, enabling simultaneous recording in the same subjects, elevating concerns of comparing data from different labs collected in different individuals with different implants and different tasks.

This central hypothesis will be tested in two broad aims, for which we have substantial preliminary data. Aim 1 will examine the control of the body by the two areas. It is hypothesized that M1 will demonstrate strong specificity for the contralateral limb (implants will be made in the hand knob) whereas PPC will code movements for most of the body and on both contra and ipsilateral sides by leveraging its partially mixed encoding of parameters (subaim 1a). Whereas M1 is hypothesized to code spatial variables exclusively during attempted or imagined actions, it is hypothesized that PPC also encodes cognitive spatial variables in task appropriate reference frames (subaim 1b). In subaim 1c we will examine how multiple body parts are combined in movement representations, hypothesizing that M1 and PPC will employ a diverse set of mechanisms including linear summation, non-linear combinations, and movement suppression expressed in different ways as a function of brain area and the specific movement set.

Aim 2 will examine the temporal aspects of encoding in the two areas. In subaim 2a we will test the hypothesis that the neural dynamics during sustained periods of movement are largely unchanging in both areas. In subaim 2b we hypothesize that, during sequential movements, M1 codes only the ongoing movement whereas PPC codes both the current and subsequent movements. Finally, in subaim 2c we will examine the coding of movement speed, with the hypothesis that there are separate subspaces in both M1 and PPC for direction and speed of movement.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Visuomotor Prosthetic for Paralysis
Actual Study Start Date : October 1, 2013
Estimated Primary Completion Date : April 30, 2026
Estimated Study Completion Date : July 31, 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Paralysis

Arm Intervention/treatment
Experimental: Neural Communication System
The Neural Communication System consists of two Neuroport Multi-Port Arrays, which are descried in detail in the intervention description. One Neuroport Multi-Port Array is inserted into the posterior parietal cortex, an area of the brain used in reach planning. The second Neuroport Multi-Port Array is inserted into the motor cortex, which is primarily responsible for controlling movement. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subject will participate in study sessions 3-5 times per week in which they will learn to use thought to control a simple computer environment or a tablet computer.
Device: Neural Communication System
NeuroPort Arrays allow for the local recording of cerebral cortex. The Neural Communication system is primarily composed of two NeuroPort Arrays. The two arrays of one MultiPort device will be placed in the primary motor cortex for recording (Platinum-tipped electrodes); and the two arrays of the additional MultiPort device be placed in the superior parietal lobule for recording (Platinum-tipped electrodes). Each MultiPort device consists of two arrays, each with 100 electrodes in a 10 x 10 configuration, with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D) or 4 mm x 4 mm x 1.0 mm, and a titanium percutaneous connector, 19 mm diameter at the base. Each MultiPort can have a total of 128 active channels (capable of transmitting neural signals to the percutaneous connector) across the two arrays. In our design, we will split active channels evenly between the two arrays resulting in 64 active channels per array.
Other Name: NeuroPort Multi-Port Array




Primary Outcome Measures :
  1. Subject control of a tablet computer [ Time Frame: Six years after array implantation ]
    Assessments will be compared with chance and previous reports of BMI efficacy using control signals derived from primary motor cortex. Computer-interface competency examination that measures the ability of the subject to control various aspects of the tablet user interface. Additionally we will measure the Quality of Life Inventory (QOLI) at regular intervals over the duration of the study. Changes in performance over time.

  2. Absence of infection or irritation [ Time Frame: Six years after array implantation ]

    The Serious Adverse event (SAE) rate will be calculated as the number of SAEs per implant-days. The SAE rate will be continuously compared to the 1% threshold level. CT scan; inspection of patient's scalp for evidence of reddening or discharge; review of new symptoms including possible fever, headache, visual or auditory changes, or change in mood or behavior; serial neurologic exams. The condition of the area will be compared with its condition on previous visits. History will be obtained regarding new symptoms.

    Neurologic exam will be compared to baseline neurologic exam




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pathology resulting in paralysis
  • Age 22-65 years
  • Able to provide informed consent
  • Understand and comply with instructions, if necessary, with the aid of a translator
  • Able to communicate via speech
  • Surgical clearance
  • Life expectancy greater than 12 months
  • Live within 60 miles of study location and willing to travel up to 5 days per week
  • A regular caregiver to monitor the surgical site
  • Psychosocial support system
  • Stable ventilator status

Exclusion Criteria:

  • Intellectual impairment
  • Psychotic illness or chronic psychiatric disorder, including major depression if untreated
  • Poor visual acuity
  • Pregnancy
  • Active infection or unexplained fever
  • Scalp lesions or skin breakdown
  • HIV or AIDS infection
  • Active cancer or chemotherapy
  • Medically uncontrolled diabetes
  • Autonomic dysreflexia
  • History of seizure
  • Implanted hydrocephalus shunt
  • History of supratentorial brain injury or neurosurgery
  • Medical conditions contraindicating surgery and chronic implantation of a medical device
  • Unable to undergo MRI or anticipated need for MRI during study
  • Nursing an infant or unwilling to bottle-feed infant
  • Chronic oral or intravenous use of steroids or immunosuppressive therapy
  • Suicidal ideation
  • Drug or alcohol dependence
  • Planning to become pregnant, or unwilling to use adequate birth control
  • Implanted Cardiac Defibrillator, Pacemaker, vagal nerve stimulator, or spinal cord stimulator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01958086


Contacts
Layout table for location contacts
Contact: Ausaf Bari, MD, PhD 310-825-5111 ABari@mednet.ucla.edu
Contact: Emily Rosario, PhD 909.596.7733 ext 3036 ERosario@casacolina.org

Locations
Layout table for location information
United States, California
University of California Los Angeles Recruiting
Los Angeles, California, United States, 90095
Contact: Ausaf Bari         
California Institute of Technology Active, not recruiting
Pasadena, California, United States, 91125
Casa Colina Centers for Rehabilitation Recruiting
Pomona, California, United States, 91769
Contact: Emily Rosario, PhD    909-596-7733 ext 3036    erosario@casacolina.org   
Sponsors and Collaborators
Richard A. Andersen, PhD
University of California, Los Angeles
Casa Colina Hospital and Centers for Healthcare
Investigators
Layout table for investigator information
Principal Investigator: Richard A Andersen, PhD California Institute of Technology
Principal Investigator: Ausaf Bari, MD, PhD University of California, Los Angeles
Principal Investigator: Emily Rosario, PhD Casa Colina Hospital and Centers for Healthcare
Layout table for additonal information
Responsible Party: Richard A. Andersen, PhD, James G. Boswell Professor of Neuroscience, California Institute of Technology
ClinicalTrials.gov Identifier: NCT01958086    
Other Study ID Numbers: G120287
13-000576 ( Other Identifier: UCLA IRB application number )
First Posted: October 8, 2013    Key Record Dates
Last Update Posted: April 13, 2022
Last Verified: April 2022
Keywords provided by Richard A. Andersen, PhD, California Institute of Technology:
Neural
Prosthetic
brain machine interface
brain computer interface
brain control
paralysis
tetraplegia
quadriplegia
spinal cord injury
Additional relevant MeSH terms:
Layout table for MeSH terms
Paralysis
Quadriplegia
Neurologic Manifestations
Nervous System Diseases